DANSKE KRÆFTFORSKNINGSDAGE 2025

Targeteret behandling og investigatorinitieret forskning

Dag R. Stormoen, Læge, PhD

#DKD2025
#SamarbejdeOmKræft

Slido
#131525

Dag Stormoen, PhD, 1. reservelæge onkologi



Blærekræft

~ 2.000 nye tilfælde pr år (900 invasive). 600 dødsfald årligt i Danmark

Stadieindeling

T:



N: Lymfeknudemetastaser

M: knogle, lever, lunger

Stadie på diagnosetidspunkt



Stadie på diagnosetidspunkt stærkt associeret med overlevelse:

Stadie	5års overlevelse
NMIBC	>90%
MIBC	40%-80%
M+	<20%



Intro i Onkologi: April 2017

2025


Mest aktive behandlinger
Mindst aktive behandlinger
Lokalavanceret inoperabel eller metastatisk blærekræft
Egnet til kombinationskemoterapi
Uegnet til kombinationskemoterapi
Egnet til Immunterapi
Uegnet til Immunterapi
Egnet Enfortumab vedotin (EV)
Uegnet EV Egnet Cisplatin
Uegnet EV Uegnet Cisplatin
Egnet Cisplatin
Uegnet Cisplatin
PD-L1 positiv
PD-L1 negativ
1. Linje
Pembrolizumab og Enfortumab Vedotin
Nivolumab, Cisplatin og Gemcitabin
Carboplatin og Gemcitabin
Cisplatin og Gemcitabin
Carboplatin og Gemcitabin
Immunterapi
Best supportive care
Progression
Progression
Stabil sygdom
Progression
Progression
Progression
2. Linje
Egnet Cisplatin
Uegnet Cisplatin
Avelumab vedligehold
Atezolizumab
Vinflunin
FGFR3 alterationer
Ikke muteret
Cisplatin og Gemcitabin
Carboplatin og Gemcitabin
Erdafitinib
Best supportive care
Progression
Progression
Progression
Progression
Progression
2./3. Linje
FGFR3 alterationer
Ikke muteret
Protokol eller Best supportive care
Best supportive care
Erdafitinib
Vinflunin
Progression
Progression
3./4. Linje
Vinflunin
Protokol eller Best supportive care
Progression
Protokol eller Best supportive care

Klinisk udfordring ved Blærekræft

High genomic heterogeneity, limited targeted options beyond FGFR3

Treatment resistance

Unmet need in later lines

#DKD2025
#SamarbejdeOmKræft

Hvorfor Investigator-Initieret forskning?

Adresserer uopfyldte behov, der ikke er dækket af industri forsøg.

Hypotesedrevne, biomarkørbaserede protokoller

Fleksibilitet til at teste nye targets og mindre subgrupper.

Childrens memorial hospital Boston

Kræftens
bekæmpelse

Zoltan Szallasi

Harvard medical school

Dana Farber Cancer Institute

Katrine Ørum,
MD, PhD Student

Kent Mouw

Dana Farber Cancer Institute / Harvard Medical School

- 2 months on location
- 12 months of campus
- Boston, Massachusetts, USA

Are there other agents beyond cisplatin that can specifically target NER deficient tumors?

- Up to 50% of bladder cancer patients are ineligible to receive cisplatin due to comorbidity (renal insufficiency, neuropathy, hearing loss, etc)

- Cisplatin resistance is common with median OS <1 year

Irofulven

"irofulven administered at this dose and schedule was well-tolerated but had modest activity as a single agent"

Schilder et al. 2010

↓

2nd Gen Irofulven (LP-184)

A



Illudin S



Illudin M

B

Omphalotus olearius



R = H

R = CH_2OH

Acylfulven (AF)

Irofulven (HMAF)

C



Irofulven is active in NER-deficient tumors *in vivo*

NER proficient



NER deficient









Börcsök et al. Clin Cancer Res 2021

PTGR-1



PTGR1 staining intensities in the mUC cohort.

40% af mBC → høj ekspression





NER-deficiency

Childrens memorial hospital Boston

Kræftens bekæmpelse

Zoltan Szallasi

Harvard medical school

Dana Farber Cancer Institute

Katrine Ørum,
MD, PhD Student

Kent Mouw

Klinisk Implementering af Dansk Investigator-Initiated Forsøg

Design og rammer for biomarkørselektiv klinisk trial

Parameter	Beskrivelse
Population	Metastatisk urothelial carcinom, PTGR1+, NER/DDR-deficient
Setting	2. / 3. linje behandling
Lægemiddel	Irofulven/LP-184
Design	Phase 1 / 2, dose escalation, single-arm, biomarkørselekteret kohorte
Endpoints	Effektmåling, sikkerhed, yderligere biomarkør-validering

Den Danske Fordel.

- Nationale registre og biobanker muliggør hurtig patientidentifikation
- Håndterbare omkostninger sammenlignet med store pharma forsøg
- Infrastruktur med solidt national samarbejde muliggør hurtig implementering af protokol

#DKD2025
#SamarbejdeOmKræft

Nationalt samarbejde



Transatlantisk samarbejde med DFCI/Harvard

Translationelt samarbejde med KB

Finansiering

Protokol

Lægemiddel (fra Lantern)

#DKD2025
#SamarbejdeOmKræft

Slido
#131525

REGION H Rigshospitalet

Dana-Farber Cancer Institute

KØBENHAVNS UNIVERSITET

Danish Cancer Society

HARVARD MEDICAL SCHOOL

REGION SJÆLLAND
NÆSTVED SYGEHUS
– vi er til for dig

nucog

Lantern Pharma

8/27/2025